top of page

FTC: PBMs gained billions by marking up drug prices, spread pricing

Writer's picture: Tex PatientsTex Patients

The report is the second from the agency’s investigation of PBMs and comes amid a flurry of lawsuits.


The Federal Trade Commission (FTC) on January 14 released its second report on pharmacy benefit managers (PBMs), this time alleging the companies marked up prices for cancer, HIV, and other medications by up to “thousands of percent.”


The findings are part of the agency’s multiyear investigation into PBMs that began in 2022. The report focuses on the three largest PBMs in the US—CVS Health’s CVS Caremark, Cigna’s Express Scripts, and UnitedHealth Group’s Optum Rx—and how they influenced the prices of specialty generic medicines.


“FTC staff have found that the big three PBMs are charging enormous markups on dozens of lifesaving drugs,” Hannah Garden-Monheit, director of the FTC’s Office of Policy Planning, said in a statement. “We also found that this problem is growing at an alarming rate, which means there is an urgent need for policymakers to address it.”


2 views0 comments

Comments


TCFP_TX_Logo.png
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn

Paid for by the Texas Coalition for Patients

bottom of page